您的位置：首页 > 产品中心 > 202825-46-5， Safinamide mesylate salt
Safinamide mesylate salt
产品价格查看更多规格...
| 产品编号 | 包装单位 | 单价(元) | 国内现货 | 国外库存 | 询价单 |
| 3216519 | 5 MG | 1320 | 2-5天 | 4-6周 | |
| 3216519 | 25 MG | 4860 | 2-5天 | 4-6周 |
产品别名
202825-46-5
Safinamide mesylate salt
(S)-(+)-2-[[4-(3-Fluorobenzoxy)benzyl]amino]propanamide; (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamide; FCE-26743; PNU-151774E, NW-1015;
结构式
基本信息
| Empirical Formula【经验(实验)分子式】 | C17H19FN2O2 · xCH4O3S |
| Molecular weight | 302.34 (free base basis) |
| MDL number | MFCD15145475 |
| PubChem Substance ID【PubChem化学物质编号】 | 329825096 |
| NACRES | NA.77 |
| Application【应用】 | Safinamide mesylate salt has been used as a reference drug to study its inhibitory effect on human monoamine oxidases (hMAO-A and hMAO-B). Safinamide mesylate salt may be used in cell signaling studies. |
| Biochem/physiol Actions【生化/生理作用】 | Safinamide is a highly selective and reversible monoamine oxidase type B (MAO-B) inhibitor that increases neostriatal dopamine concentration. In addition, safinamide is voltage-dependent sodium and calcium channel blocker. It appears to bind to the batrachotoxin-sensitive site 2 of the voltage-sensitive sodium channels. Safinamide blocks N and L-type calcium channels and inhibits glutamate and aspartate release from synaptic terminals. Safinamide mesylate prevents dopamine reuptake and is effective in the treatment of epilepsy and Parkinson′s disease. |
| Features and Benefits【特点和优势】 | This compound is featured on the Calcium Channels and Dopamine and Norepinephrine Metabolism pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here. |
产品性质
| Quality Level【质量水平】 | 100 |
| Assay【测定】 | ≥98% (HPLC) |
| form【形式】 | powder |
| optical activity【旋光性】 | [α]/D +9.5 to +14°, c = 1 (95% acetic acid) |
| color【颜色】 | white to tan |
| solubility【溶解性】 | H2O: ≥15 mg/mL |
| storage temp.【储存温度】 | 2-8℃ |
| SMILES string | CS(O)(=O)=O.C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O |
| InChI | 1S/C17H19FN2O2.CH4O3S/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14;1-5(2,3)4/h2-9,12,20H,10-11H2,1H3,(H2,19,21);1H3,(H,2,3,4)/t12-;/m0./s1 |
| InChI key | YKOCHIUQOBQIAC-YDALLXLXSA-N |
| Gene Information | human ... MAOB(4129) |
| packaging【包装】 | 5, 25 mg in glass bottle |
安全信息
| Pictograms【象形图】 | GHS07,GHS08 |
| Signal word【警示用语：】 | Warning |
| Hazard Statements | H302 - H319 - H361d |
| Precautionary Statements | P202 - P264 - P270 - P301 + P312 - P305 + P351 + P338 - P308 + P313 |
| Hazard Classifications【危险分类】 | Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 2 |
| Storage Class Code【储存分类代码】 | 6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects |
| WGK | WGK 3 |
